Skip to main content

Advertisement

SpringerLink
Log in

Early neovascular bridging after photodynamic therapy of myopic choroidal neovascularization

  • Clinical Investigation
  • Published:
Graefe's Archive for Clinical and Experimental Ophthalmology Aims and scope Submit manuscript

Abstract

Background

Photodynamic therapy is a relatively new modality for the treatment of subfoveal choroidal neovascularization (CNV). An unusual response to verteporfin therapy of myopic CNVs is reported.

Methods

Out of 187 CNVs secondary to pathologic myopia treated with photodynamic therapy, three eyes manifested two separate foci of CNV before treatment. The three eyes were treated with verteporfin therapy according to the standard protocol, using a single spot of light that covered both neovascular fronds.

Results

All the three eyes showed neovascular bridging of the two separate neovascular complexes 1 month after treatment.

Conclusions

Eyes with multiple foci of myopic CNV may show unexpected outcomes after verteporfin therapy. Several factors, such as changes of the retinal pigment epithelium and choroidal vasculature involved in the treatment and enhanced expression of vascular endothelial growth factor, may play a role.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1a–c
Fig. 2a–c
Fig. 3a–c

Similar content being viewed by others

References

  1. Battaglia Parodi M, Da Pozzo S, Ravalico G (2003) Angiographic features after photodynamic therapy for choroidal neovascularization in age-related macular degeneration and pathologic myopia. Br J Ophthalmol 87: 177–183

    Google Scholar 

  2. Haimovici R, Kramer M, Miller JW, et al (1997) Localization of lipoprotein-delivered benzoporphyrin derivative in the rabbit eye. Curr Eye Res 16: 83–90

    Google Scholar 

  3. Husain D, Kramer M, Kenny AG (1999) Effects of photodynamic therapy using verteporfin on experimental choroidal neovascularization and normal retina and choroid up to 7 weeks after treatment. Invest Ophthalmol Vis Sci 40: 2322–2331

    CAS  PubMed  Google Scholar 

  4. Michels S, Schmidt-Erfurth U (2003) Sequence of vascular events following photodynamic therapy Invest Ophthalmol Vis Sci 44:2147–2154

    Article  Google Scholar 

  5. Ohno-Matsui K, Morita I, Tombran-Tink J, et al (2001) Novel mechanism for age-related macular degeneration: an equilibrium shift between the angiogenesis factors VEGF and PEDF. J Cell Physiol 189: 323–333

    Google Scholar 

  6. Olsen TW, Capone A, Sternberg P, et al (1996) Subfoveal choroidal neovascularization in punctate inner choroidopathy. Surgical management and pathologic findings. Ophthalmology 103: 2061–2069

    CAS  PubMed  Google Scholar 

  7. Schmidt-Erfurth U, Miller J, Sickenberg M, et al (1998) Photodynamic therapy of subfoveal choroidal neovascularization: clinical and angiographic examples. Graefes Arch Clin Exp Ophthalmol 236: 365–374

    CAS  PubMed  Google Scholar 

  8. Schmidt-Erfurth U, Michels S, Barbazetto I, Laqua H (2002) Photodynamic effects on choroidal neovascularizations and physiological choroid. Invest Ophthalmol Vis Sci 43:830–841

    PubMed  Google Scholar 

  9. Schmidt-Erfurth U, Schlotzer-Schrehard U, Cursiefen C, Michels S, Beckendorf A, Naumann GO (2003) Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium-derived factor. Invest Ophthalmol Vis Sci 44:4473–4480

    Article  PubMed  Google Scholar 

  10. Soubrane G, Coscas G, Kuhn D (1999) Myopia. In Guyer DR, Yannuzzi LA, Chang S, Shields JA, Green WR (eds) Retina, vitreous, macula. Saunders, Philadelphia, pp 189–205

  11. Verteporfin in Photodynamic Therapy (VIP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. 1-year results of a randomized clinical trial—VIP report no. 1 (2001) Ophthalmology 108: 841–852

    Article  PubMed  Google Scholar 

  12. Verteporfin in Photodynamic Therapy (VIP) Study Group (2003) Verteporfin therapy in subfoveal choroidal neovascularization in pathologic myopia. 2-year results of a randomised clinical trial—VIP report no. 3. Ophthalmology 110: 667–673

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Ophthalmology, University of Udine, Piazzale S. Maria della Misericordia, 33100, Udine, Italy

    Paolo Lanzetta, Massimo Ambesi-Impiombato & Francesco Bandello

  2. Eye Clinic, University of Trieste, Trieste, Italy

    Maurizio Battaglia Parodi & Giuseppe Ravalico

Authors
  1. Paolo Lanzetta
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Maurizio Battaglia Parodi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Massimo Ambesi-Impiombato
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Giuseppe Ravalico
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Francesco Bandello
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Paolo Lanzetta.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lanzetta, P., Battaglia Parodi, M., Ambesi-Impiombato, M. et al. Early neovascular bridging after photodynamic therapy of myopic choroidal neovascularization. Graefe's Arch Clin Exp Ophthalmol 242, 840–844 (2004). https://doi.org/10.1007/s00417-004-0904-0

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00417-004-0904-0

Keywords

Search

Navigation